Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWN NASDAQ:KRYS NASDAQ:NUVL NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsKRYSKrystal Biotech$286.23+0.6%$262.18$122.80▼$303.00$8.42B0.5291,461 shs120,859 shsNUVLNuvalent$103.72+2.2%$101.96$63.56▼$113.01$8.15B1.15561,179 shs87,716 shsPCVXVaxcyte$56.60+1.7%$58.67$28.09▼$65.00$8.16B1.31.33 million shs703,866 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%0.00%+0.37%+100.47%+187.83%KRYSKrystal Biotech+6.97%+5.68%+9.05%+5.74%+75.35%NUVLNuvalent+2.45%-0.46%-3.76%-3.35%+34.52%PCVXVaxcyte-2.34%-5.34%-4.77%+0.57%+62.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsKRYSKrystal Biotech$286.23+0.6%$262.18$122.80▼$303.00$8.42B0.5291,461 shs120,859 shsNUVLNuvalent$103.72+2.2%$101.96$63.56▼$113.01$8.15B1.15561,179 shs87,716 shsPCVXVaxcyte$56.60+1.7%$58.67$28.09▼$65.00$8.16B1.31.33 million shs703,866 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%0.00%+0.37%+100.47%+187.83%KRYSKrystal Biotech+6.97%+5.68%+9.05%+5.74%+75.35%NUVLNuvalent+2.45%-0.46%-3.76%-3.35%+34.52%PCVXVaxcyte-2.34%-5.34%-4.77%+0.57%+62.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 2.00Hold$23.298.15% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.1113.23% UpsideNUVLNuvalent 2.88Moderate Buy$137.2532.33% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0051.94% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, KRYS, PCVX, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/21/2026NUVLNuvalent Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NUVLNuvalent HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$155.004/9/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)4/8/2026PCVXVaxcyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026NUVLNuvalent WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$125.003/30/2026NUVLNuvalent Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$116.003/27/2026KRYSKrystal Biotech Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform3/25/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$158.18M14.06N/AN/A$4.30 per share5.01KRYSKrystal Biotech$389.13M21.65$7.27 per share39.36$43.37 per share6.60NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/APCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$107.32M-$1.03N/A2,153.00N/A-67.85%-23.43%-20.69%N/AKRYSKrystal Biotech$204.83M$6.8538.2526.04N/A53.92%19.25%17.62%N/ANUVLNuvalent-$425.38M-$5.85N/AN/AN/AN/A-39.29%-35.01%5/7/2026 (Estimated)PCVXVaxcyte-$766.63M-$5.62N/AN/AN/AN/A-25.88%-23.85%5/6/2026 (Estimated)Latest DAWN, KRYS, PCVX, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NUVLNuvalent-$1.35N/AN/AN/A$0.49 millionN/A5/6/2026Q1 2026PCVXVaxcyte-$1.7411N/AN/AN/A$12.50 millionN/A5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million2/24/2026Q4 2025DAWNDay One Biopharmaceuticals-$0.17-$0.21-$0.04-$0.2060$49.81 million$53.72 million2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/A2/17/2026Q4 2025KRYSKrystal Biotech$1.62$1.70+$0.08$1.70$105.30 million$107.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A8.027.91KRYSKrystal BiotechN/A9.959.56NUVLNuvalentN/A15.2715.27PCVXVaxcyteN/A7.917.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%KRYSKrystal Biotech86.29%NUVLNuvalent97.26%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%KRYSKrystal Biotech13.10%NUVLNuvalent10.20%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60103.33 million96.93 millionOptionableKRYSKrystal Biotech21029.44 million25.58 millionOptionableNUVLNuvalent4078.62 million70.60 millionOptionablePCVXVaxcyte160144.39 million139.91 millionOptionableDAWN, KRYS, PCVX, and NUVL HeadlinesRecent News About These CompaniesVaxcyte, Inc. $PCVX Shares Purchased by UBS Group AGMay 6 at 8:25 AM | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Price Down 6.8% - What's Next?May 5 at 6:18 PM | marketbeat.comVanguard Group Inc. Sells 126,467 Shares of Vaxcyte, Inc. $PCVXMay 5 at 8:19 AM | marketbeat.comJennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVXMay 2, 2026 | marketbeat.comVaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV MarketMay 1, 2026 | seekingalpha.comVaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in StockMay 1, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVXMay 1, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Cut to "Strong Sell" at Wall Street ZenMay 1, 2026 | americanbankingnews.comPictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVXApril 30, 2026 | marketbeat.comVaxcyte (PCVX) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Rating Lowered to Strong Sell at Wall Street ZenApril 28, 2026 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 26, 2026 | marketbeat.com5 Best 52-Week High US Stocks to BuyApril 23, 2026 | insidermonkey.comVaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial StageApril 23, 2026 | insidermonkey.comVaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street ZenApril 20, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Rating Lowered by Wall Street ZenApril 12, 2026 | marketbeat.comIs It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?April 11, 2026 | finance.yahoo.comElvia Cowan Sells 3,000 Shares of Vaxcyte (NASDAQ:PCVX) StockApril 9, 2026 | insidertrades.comInsider Selling: Vaxcyte (NASDAQ:PCVX) CAO Sells 3,000 Shares of StockApril 8, 2026 | marketbeat.comVaxcyte to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 7, 2026 | globenewswire.comVaxcyte joins elite club of stocks with RS ratings over 90March 31, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDAWN, KRYS, PCVX, and NUVL Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWNDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Krystal Biotech NASDAQ:KRYS$286.23 +1.66 (+0.58%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$103.72 +2.25 (+2.22%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Vaxcyte NASDAQ:PCVX$56.60 +0.96 (+1.73%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
